Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1970 1
1971 1
1972 1
1973 1
1975 2
1977 2
1978 1
1979 2
1980 7
1981 4
1982 5
1983 5
1984 1
1985 2
1986 4
1987 2
1988 2
1989 1
1990 2
1992 1
1993 3
1994 3
1995 1
1996 1
1997 1
1998 6
1999 1
2000 2
2001 3
2002 5
2003 4
2004 6
2005 3
2006 5
2007 4
2008 9
2009 6
2010 6
2011 8
2012 8
2013 11
2014 5
2015 8
2016 15
2017 12
2018 11
2019 9
2020 16
2021 22
2022 11
2023 16
2024 7

Text availability

Article attribute

Article type

Publication date

Search Results

247 results

Results by year

Filters applied: . Clear all
Page 1
Oral candidiasis.
Millsop JW, Fazel N. Millsop JW, et al. Clin Dermatol. 2016 Jul-Aug;34(4):487-94. doi: 10.1016/j.clindermatol.2016.02.022. Epub 2016 Mar 2. Clin Dermatol. 2016. PMID: 27343964 Review.
Human STAT1 Gain-of-Function Heterozygous Mutations: Chronic Mucocutaneous Candidiasis and Type I Interferonopathy.
Okada S, Asano T, Moriya K, Boisson-Dupuis S, Kobayashi M, Casanova JL, Puel A. Okada S, et al. J Clin Immunol. 2020 Nov;40(8):1065-1081. doi: 10.1007/s10875-020-00847-x. Epub 2020 Aug 27. J Clin Immunol. 2020. PMID: 32852681 Free PMC article. Review.
Heterozygous gain-of-function (GOF) mutations in STAT1 in patients with chronic mucocutaneous candidiasis (CMC) and hypothyroidism were discovered in 2011. ...
Heterozygous gain-of-function (GOF) mutations in STAT1 in patients with chronic mucocutaneous candidiasis (CMC) and hyp …
Mucocutaneous candidiasis.
Rowen JL. Rowen JL. Semin Perinatol. 2003 Oct;27(5):406-13. doi: 10.1016/s0146-0005(03)00066-1. Semin Perinatol. 2003. PMID: 14626505 Review.
Mucosal candidiasis.
Vazquez JA, Sobel JD. Vazquez JA, et al. Infect Dis Clin North Am. 2002 Dec;16(4):793-820, v. doi: 10.1016/s0891-5520(02)00042-9. Infect Dis Clin North Am. 2002. PMID: 12512182 Review.
This article examines the ecology and epidemiology of gastrointestinal candidiasis, esophageal candidiasis, chronic mucocutaneous candidiasis, urinary tract candidiasis, and vulvovaginal candidiasis. ...
This article examines the ecology and epidemiology of gastrointestinal candidiasis, esophageal candidiasis, chronic mucocutaneous
Chronic mucocutaneous candidiasis.
Kirkpatrick CH. Kirkpatrick CH. Pediatr Infect Dis J. 2001 Feb;20(2):197-206. doi: 10.1097/00006454-200102000-00017. Pediatr Infect Dis J. 2001. PMID: 11224843 Review.
Chronic mucocutaneous candidiasis should be viewed as a spectrum of disorders in which the patients have persistent and/or recurrent candidiasis of the skin, nails and mucous membranes. ...
Chronic mucocutaneous candidiasis should be viewed as a spectrum of disorders in which the patients have persistent and
Chronic Candidiasis in Children.
Green L, Dolen WK. Green L, et al. Curr Allergy Asthma Rep. 2017 May;17(5):31. doi: 10.1007/s11882-017-0699-9. Curr Allergy Asthma Rep. 2017. PMID: 28429308 Review.
PURPOSE OF REVIEW: Healthy children may develop candidal infections as the result of exposure to antibiotics or corticosteroids, but chronic candidiasis in children after the newborn period is unusual. Chronic mucocutaneous candidiasis (CMC) refers to a group …
PURPOSE OF REVIEW: Healthy children may develop candidal infections as the result of exposure to antibiotics or corticosteroids, but chronic …
Primary immunodeficiency and chronic mucocutaneous candidiasis: pathophysiological, diagnostic, and therapeutic approaches.
Egri N, Esteve-Solé A, Deyà-Martínez À, Ortiz de Landazuri I, Vlagea A, García AP, Cardozo C, Garcia-Vidal C, Bartolomé CS, Español-Rego M, Yiyi L, Bosch-Amate X, Ferrando J, Yagüe J, Juan M, Alsina L. Egri N, et al. Allergol Immunopathol (Madr). 2021 Jan 2;49(1):118-127. doi: 10.15586/aei.v49i1.20. eCollection 2021. Allergol Immunopathol (Madr). 2021. PMID: 33528939 Review.
Chronic mucocutaneous candidiasis (CMC) is characterized by a chronic or recurrent non-invasive infection, mainly due to Candida albicans, in skin, nails, and mucous membranes, associated in some cases with autoimmune manifestations. ...
Chronic mucocutaneous candidiasis (CMC) is characterized by a chronic or recurrent non-invasive infection, mainly due t
Main human inborn errors of immunity leading to fungal infections.
Cifaldi C, Ursu GM, D'Alba I, Paccoud O, Danion F, Lanternier F, Chiriaco M. Cifaldi C, et al. Clin Microbiol Infect. 2022 Nov;28(11):1435-1440. doi: 10.1016/j.cmi.2022.06.031. Epub 2022 Jul 19. Clin Microbiol Infect. 2022. PMID: 35863627 Free article. Review.
Candida fungal infection that sometimes strikes healthy subjects is responsible for the chronic mucocutaneous candidiasis that is one of the principal clinical manifestations occurring in several rare primary immunodeficiencies associated with an inborn error …
Candida fungal infection that sometimes strikes healthy subjects is responsible for the chronic mucocutaneous candidiasis
Chronic mucocutaneous candidiasis: what can we conclude about IL-17 antagonism?
Veverka KK, Feldman SR. Veverka KK, et al. J Dermatolog Treat. 2018 Aug;29(5):475-480. doi: 10.1080/09546634.2017.1398396. Epub 2017 Nov 21. J Dermatolog Treat. 2018. PMID: 29076381 Review.
PURPOSE: IL-17 antagonists are effective for psoriasis in clinical trials, but long-term safety is not fully characterized. Since chronic mucocutaneous candidiasis (CMC) is caused by defects in the IL-17 pathway, CMC risk data have been touted as providing re …
PURPOSE: IL-17 antagonists are effective for psoriasis in clinical trials, but long-term safety is not fully characterized. Since chronic
247 results